Skip to main content
Home
  • MEDIS MEDIS
    • Presentation
    • MEDIS's story
    • Human Resources
    • Production Site
    • Press Release
  • Subsidiaries Subsidiaries
    • Neapolis
    • Medis sénégal Medis sénégal
    • inphamédis
  • Therapeutic Areas
    • Allergology
    • Anesthesiology
    • Analgesia
    • Anti-Inflammatories
    • Dietary supplements
    • Cardiology
    • Gynecology
    • Gastroenterology
    • Hematology
    • Immunosuppression
    • Infectiology
    • Metabolism and Nutrition
    • Neurology
    • Ophthalmology
    • Psychiatry
    • Rheumatology
    • Radiology
    • Urology – Nephrology
  • Our Drugs
    • Products catalog
    • PSYCHIATRY
    • ALLERGOLOGY
    • GASTROENTEROLOGY
    • RADIOLOGIE
    • ANALGESIA
    • ANTI-INFLAMMATORY
    • INFECTIOLOGY
    • CARDIOLOGY
    • DIETARY SUPPLEMENTS
    • ANESTHESIOLOGY
    • GYNECOLOGY
    • HEMATOLOGY
    • IMMUNOLOGY
    • METABOLISM AND NUTRITION
    • NEUROLOGY
    • OPHTHALMOLOGY

    View all domains

    Glargen

    Glargen 100UI/ml

    Metabolism and nutrition

  • Library
    • Scientific publications
    • Health Capsules
    • Articles
    • Medis News
    • Mediatheque
  • Contact

Recherche

  • English
  • Français
  1. Accueil
  2. Node

REMIFENTANIL MEDIS 1 MG BT 5

  • Read more about REMIFENTANIL MEDIS 1 MG BT 5

REMIFENTANIL is indicated as an analgesic agent during the induction and/or maintenance of general anesthesia. REMIFENTANIL is indicated for analgesia in patients aged 18 years and older who are mechanically ventilated in an intensive care unit.

REMIFENTANIL 5 MG BT 5

  • Read more about REMIFENTANIL 5 MG BT 5

REMIFENTANIL is indicated as an analgesic agent during the induction and/or maintenance of general anesthesia. REMIFENTANIL is indicated for analgesia in patients aged 18 years and older who are mechanically ventilated in an intensive care unit.

REMIFENTANIL 1 MG BT 5

  • Read more about REMIFENTANIL 1 MG BT 5

REMIFENTANIL is indicated as an analgesic agent during the induction and/or maintenance of general anesthesia. REMIFENTANIL is indicated for analgesia in patients aged 18 years and older who are mechanically ventilated in an intensive care unit.

RETAZID 160 MG / 25 MG BT 30

  • Read more about RETAZID 160 MG / 25 MG BT 30

This medication is indicated in non-insulin-dependent (type 2) diabetes mellitus in adults, when diet, exercise, and weight reduction alone are not sufficient to restore glycemic balance.

RETAZID 160 MG / 25 MG BT 90

  • Read more about RETAZID 160 MG / 25 MG BT 90

Treatment of essential hypertension in adults. RETAZID, a fixed-dose combination, is indicated in patients whose blood pressure is not adequately controlled with valsartan or hydrochlorothiazide monotherapy.

RETAZID 160 MG / 12.5 MG BT 90

  • Read more about RETAZID 160 MG / 12.5 MG BT 90

Treatment of essential hypertension in adults. RETAZID, a fixed-dose combination, is indicated in patients whose blood pressure is not adequately controlled with valsartan or hydrochlorothiazide monotherapy.

RETAZID 160 MG / 12.5 MG BT 30

  • Read more about RETAZID 160 MG / 12.5 MG BT 30

Treatment of essential hypertension in adults. RETAZID, a fixed-dose combination, is indicated in patients whose blood pressure is not adequately controlled with valsartan or hydrochlorothiazide monotherapy.

RETAZID 80 MG / 12.5 MG BT 30

  • Read more about RETAZID 80 MG / 12.5 MG BT 30

Treatment of essential hypertension in adults. RETAZID, a fixed-dose combination, is indicated in patients whose blood pressure is not adequately controlled with valsartan or hydrochlorothiazide monotherapy.

RETAZID 80 MG / 12.5 MG BT 90

  • Read more about RETAZID 80 MG / 12.5 MG BT 90

Treatment of essential hypertension in adults. RETAZID, a fixed-dose combination, is indicated in patients whose blood pressure is not adequately controlled with valsartan or hydrochlorothiazide monotherapy.

STOPALGIC 1000 MG BT 8

  • Read more about STOPALGIC 1000 MG BT 8

Symptomatic treatment of mild to moderate pain and/or fever. This presentation is reserved for adults and children weighing at least 27 kg (approximately 8 years old).

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Current page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Footer menu

  • News
  • Partnership
  • Career
  • Useful links
  • FAQ
  • EMC PREMIUM
  • Request a quote
  • General Terms and Conditions of Use
  • Site Map

Contact us

Address : Route de Tunis Km 7 - BP 206 Nabeul 8000 - Tunisie.

Phone : +216.72.235.006 (L.G.) | Fax : +216.72.235.016

Email : contact@labomedis.com

Web site : www.medis.com.tn

  • fb
  • in
  • youtube
  • insta

See our K.S.A products

Arabie saudi

© MEDIS 2022 | Website developed by www.medianet.com.tn

Also visit : vitawin-medis.com @moncandys